According to the company, the vaccine is developed and manufactured at Bharat Biotech’s BSL-3 biocontainment facility.
“This is an unprecedented vaccine trial to be conducted in India, and we are overwhelmed by the steady increase in participation. We sincerely thank all 13,000 volunteers across the country for their support in enabling us to bring out a safe and effective Indian vaccine for COVID-19. This public health volunteerism for vaccines is a moral boost for us to achieve our historic goal of 26,000 soon. Thank you volunteers Thank you India ”, said Dr. Suchitra Ella from Bharat Biotech.
Covaxin, Bharat Biotech’s indigenous Covid-19 vaccine from India is developed in collaboration with the Indian Council for Medical Research (ICMR) – National Institute of Virology (NIV).
This indigenous inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) biocontainment facility, the only one of its kind in the world. Covaxin is a highly purified and inactivated 2-dose SARS-CoV2 vaccine manufactured on a Vero cell manufacturing platform with an excellent safety record of more than 300 million doses.
.
